Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo.AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review